Reprogram Biosciences has quietly raised seed funding to pursue what might sound like science fiction: using messenger RNA to transform cancer cells into allies of the immune system. CEO Rustam Esanov says the San Carlos-based startup has brought in capital from Unshackled Ventures, 1517 Fund, and Narya, the early-stage venture firm co-founded by JD Vance and Colin Greenspon back in 2019. As of May 2026, total funding raised since the company's founding stands at $6 million—modest by biotech standards, but enough to get the science off the ground.
The premise is ambitious, perhaps more so than the founders initially let on. Rather than attacking tumors directly or simply boosting immune responses, Reprogram wants to hijack cancer cells themselves, reprogramming them into antigen-presenting cells—the very type of cell that should, under normal circumstances, sound the alarm to T cells and other immune defenders. If it works, the company says, even the most hostile tumor microenvironments could be turned into what they call "immune priming" sites, capable of triggering system-wide anti-tumor activity.
It's a crowded moment for cellular reprogramming. Asgard Therapeutics pulled in €30 million a couple years back to reprogram tumor cells into dendritic cells. Moonwalk Biosciences launched with $57 million around the same time for precision epigenetic reprogramming. And Life Biosciences recently received FDA clearance for a first-in-human trial of partial epigenetic reprogramming—admittedly in vision loss, not oncology, but a regulatory signal nonetheless that the field is maturing.
The Platform and the People
Reprogram's approach centers on delivering mRNA-encoded gene combinations directly into tumors via lipid nanoparticles—the same delivery technology that powered COVID-19 vaccines, though applied here in a vastly different context. The company's proprietary AI platform, dubbed CellRecodeX, sifts through biological foundation models to identify the right reprogramming factor combinations. It's the kind of work that requires both computational firepower and wet-lab validation, and the team Reprogram has assembled suggests they're serious about both.
CEO Rustam Esanov comes with stints at GSK, Scripps Research, and a handful of other biotechs. His co-founder and COO, Eziz Kuliyev, brings mRNA delivery expertise from UC San Diego. Angela Yang, who held leadership roles at GSK and Genentech, now leads research, with expertise in CRISPR and single-cell multi-omics. Annageldi Tayyrov, who earned his PhD at ETH Zürich and later worked at Immunai, oversees the AI side. The company's LinkedIn profile lists between two and ten employees—early days, clearly, but the credentials are there.
Colin Greenspon of Narya, commenting on the investment, highlighted the company's approach, though he stopped short of making grand predictions. Narya, based in Ohio, has drawn backing from Peter Thiel, Marc Andreessen, and Eric Schmidt—names that tend to signal serious capital and serious ambitions, even if the firm itself remains relatively low-profile compared to the Sand Hill Road giants.
What the Data Shows (and Doesn't)
Reprogram has presented at industry gatherings, including the MassBio Align Summit in 2025. The company points to prolonged survival in preclinical models, though those results haven't yet made their way into peer-reviewed journals. That's not unusual for a company this early—publication lags, and competitive dynamics often mean companies hold their cards close. Still, it's a gap worth noting.
The broader market for in vivo reprogramming therapies remains speculative, but venture investors seem willing to place bets. The idea of turning cancer cells into immunological weapons has conceptual elegance, and if the AI-driven discovery engine delivers on its promise, Reprogram could identify combinations that human intuition alone might miss. Whether that translates into clinical success is another question entirely.
Next Steps, Unclear Timeline
With seed funding secured, Reprogram plans to push its lead candidate through preclinical development while expanding its AI capabilities. The company hasn't disclosed timelines for IND-enabling studies or when it might file to begin clinical trials—standard opacity for a startup still working out the science.
Incorporated in Delaware, the company previously raised capital via a SAFE agreement, according to filings with the SEC. The new funds will support chemistry, manufacturing, and controls work—the unglamorous but essential infrastructure required before any therapy can enter human testing.
For now, Reprogram remains in the category of promising-but-unproven. The science is intriguing, the backers credible, the team experienced. Whether mRNA-driven cellular reprogramming becomes a real weapon against cancer, or just another elegant idea that stumbles in the clinic, won't be clear for some time. But in a field where breakthroughs often come from unexpected angles, it's the kind of bet that at least makes sense to take.
